valemetostat and datopotamab deruxtecan in advanced nsclc
Published 1 month ago • 87 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:05
metalmark: amivantamab and capmatinib in advanced nsclc
-
3:28
bispecific antibodies in lung cancer
-
0:44
antibody-drug conjugates for advanced bladder cancer
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
2:35
brain metastases in alk nsclc
-
1:32
dr. antoni ribas on the benefits of mapk inhibition with dabrafenib and trametinib
-
1:10
tu2218, a tgfβ-ri and vegfr2 dual inhibitor, with pembrolizumab in solid tumors
-
1:05
comparing dasatinib-blinatumomab vs ponatinib-blinatumomab in newly diagnosed ph b-all
-
1:01
fimepinostat with venetoclax in r/r lymphoma
-
6:26
alk mutations in paediatric tumours
-
0:58
progress in the treatment of alk-positive non-small cell lung cancer
-
1:45
future avenues for the use of liquid biopsies in nsclc
-
0:33
insights from dr. maya leiva: understanding hematologic disorders
-
1:58
enfortumab vedotin for the treatment of advanced urothelial cancer
-
1:25
parct: atezolizumab for ctcl and next steps
-
1:27
erdafitinib and enfortumab vedotin in pretreated fgfr2/3-mutant bladder cancer
-
14:15
the blood/brain barrier for alk patients
-
1:01
biomarkers evolve for treatment of lung cancers